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Abstract: Blockade of the renin-angiotensin system with selective AT1 receptor antagonists 
is recognized as an effective mean to lower blood pressure in hypertensive patients. Among the 
class of AT1 receptor antagonists, telmisartan offers the advantage of a very long half-life. This 
enables blood pressure control over 24 hours using once-daily administration. The combination 
of telmisartan with hydrochlorothiazide is a logical step because numerous previous studies have 
demonstrated that sodium depletion enhances the antihypertensive efﬁ  cacy of drugs interfering 
with the activity of the renin-angiotensin system (RAS). In accordance with past experience 
using similar compounds blocking the RAS, several controlled studies have now demonstrated 
that the ﬁ  xed-dose combination of telmisartan/hydrochlorothiazide is superior in lowering blood 
pressure than either telmisartan or hydrochlorothiazide alone. Of clinical interest also is the 
observation that the excellent clinical tolerance of the angiotensin II receptor antagonist is not 
affected by the association of the low-dose thiazide. Thus telmisartan/hydrochlorothiazide is an 
effective and well-tolerated antihypertensive combination. Finally, the development of ﬁ  xed-dose 
combinations should improve drug adherence because of the one-pill-a-day regimen.
Keywords: telmisartan, hydrochlorothiazide, ﬁ  xed-dose combinations, antihypertensive agent, 
safety, compliance
Introduction
Cardiovascular diseases (CVD) are the leading causes of death among adults in the 
industrialized world (29.2% of total global deaths) and in developing countries, and 
will probably remain so in the near future (WHO 2003). Hypertension is one of the 
most prevalent risk factors for the development of cardiovascular complications such 
as left ventricular hypertrophy, myocardial infarction, stroke, and renal diseases. 
However, if blood pressure (BP) is effectively controlled, target-organ damage can be 
prevented and, in the long term, the likelihood of these complications can be reduced 
(Chobanian et al 2003; Cifkova et al 2003). Its treatment is also one of the most effective 
ways to retard the progression of diabetic and non-diabetic renal diseases (Chobanian 
et al 2003; Cifkova et al 2003). Unfortunately, reports from several countries around 
the world have shown that hypertensive patients with well-controlled BP represent 
only a small percentage of the hypertensive population (usually less than 30%). This 
contrasts with the rather high response rate obtained in clinical trials investigating 
new antihypertensive drugs or therapeutic strategies. For example, in the Hyperten-
sion Optimal Treatment (HOT) study, 88% of patients assigned to a target diastolic 
BP 90 mmHg achieved this goal after 12 months of antihypertensive treatment 
(Hansson et al 1998). In the ALLHAT study, >60% of the enrolled patients achieved 
a BP goal <140/90 mmHg at 5 years (The ALLHAT Ofﬁ  cers and Coordinators for 
the ALHAT Collaborative Research Group 2002). This apparent discrepancy between 
the results obtained in the general hypertensive population and those of large clinical Vascular Health and Risk Management 2007:3(3) 266
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trials is perhaps explained by the experimental conditions 
in which clinical trials are conducted and by the selection 
of patients and physicians both being more motivated or 
willing to achieve target BP levels when engaged in clinical 
studies (Resnick 2003). Nevertheless, it strongly suggests 
that it should be possible to increase the overall percentage 
of patients reaching a satisfactory BP control. 
Today, when the patient fails to respond to treatment, the 
most common medical response is to increase the dose of the 
antihypertensive agent, to add another drug, or eventually 
to change the therapeutic agent (Waeber 2003). In some 
cases, clinical investigations looking for a secondary form 
of hypertension will be conducted. Thus, physicians have 
a systematic bias considering that the patient is basically a 
non-responder or that the pharmacological regimen is inad-
equate. This “pharmacological” attitude leads either to the 
use of high doses of antihypertensive agents which are very 
likely to produce side-effects, or to the prescription of sev-
eral antihypertensive compounds according to the classical 
step-care therapy scheme. However, both the occurrence of 
side-effects and the increased complexity of the regimen have 
been shown to reduce drug adherence and the persistence of 
treatment (Wuerzner et al 2003). 
Treating hypertension with a combination of different drugs 
has multiple rationale and advantages and might offer the possi-
bility to reduce the number of non-responders. The ﬁ  rst advantage 
is obviously to associate drugs with different mechanisms of 
action leading to an increased efﬁ  cacy of each individual drug. 
Another potential clinical interest of drug combinations is to 
blunt the activation of physiological compensatory feed-back 
mechanisms which could either interfere with the activity of a 
drug or generate side-effects. Thus, combining two agents that 
may mutually interfere with compensatory responses is more 
likely to increase the BP control rate (Waeber 2003) and may 
even prevent side-effects. Studies have clearly demonstrated that 
BP can be readily controlled in almost two-thirds of the cases by 
a carefully selected prescription of two drugs (Sica 1994; Epstein 
and Bakris 1996).
In this context, the association of a blocker of the renin-angio-
tensin system (RAS) with a diuretic is a very logical combination. 
The natriuretic effect of the diuretic which leads to a decrease in 
plasma volume stimulates renin secretion and thereby increases 
angiotensin II and aldosterone production, which in turn causes 
vasoconstriction and promotes water and sodium retention. The 
direct consequence of these physiological responses is a limita-
tion of the antihypertensive effect of the diuretic. Blockade of the 
RAS in such high-renin conditions prevents the angiotensin II-de-
pendent BP maintenance (Brunner et al 1988) and thus enhances 
the effect of the diuretic (Neutel et al 1999b). Conversely, the 
antihypertensive efﬁ  cacy of blockers of the RAS is blunted when 
patients are salt-loaded because BP becomes volume- rather than 
renin-dependent. With the addition of a diuretic, BP becomes 
more renin-dependent and the antihypertensive efﬁ  cacy of the 
blocker of the RAS is increased by the diuretic. This explains 
why a large number of ﬁ  xed-dose combinations containing RAS 
blocker and a diuretic have been developed in the past. Clinical 
as well as experimental studies have demonstrated that when 
combined with hydrochlorothiazide, angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin II receptor blockers 
(ARBs) lower BP in low-, normal-, and high-renin hypertension 
(Waeber 2003). The interest in these combinations is particularly 
evident in black populations, in whom a monotherapy with con-
ventional doses of an ACEI or an ARB is often considered less 
effective unless patients are maintained on a low-sodium intake 
(Falconnet et al 2004). Another advantage of such a combination 
is also its excellent tolerability proﬁ  le with a very low incidence 
of adverse effects, as will be discussed below.
Telmisartan/hydrochlorothiazide: 
ﬁ  xed-dose combination
Introduction to the compounds
The ARB telmisartan and the thiazide diuretic hydrochlo-
rothiazide are two antihypertensive agents that have a well-
recognized clinical efﬁ  cacy in the treatment of hypertension 
(Van Brummelen et al 1980; Almansa et al 1996; Neutel 
et al 1999a, b; McGill and Reilly 2001b; Neutel et al 2003). 
However, as generally observed in the treatment of essen-
tial hypertension, many patients are either from the time of 
diagnosis or later in their follow-up, insufﬁ  ciently controlled 
with telmisartan or hydrochlorothiazide alone (Lacourcière 
et al 2001; Lacourcière 2002; Lacourcière and Martin 2002; 
Freytag et al 2002). Therefore, ﬁ  xed-doses combination of 
telmisartan and hydrochlorothiazide (Micardis-Plus® and 
Micardis/HCT®, Boehringer Ingelheim, or PritorPlus®, 
GlaxoSmithKline) have been developed in order to further 
improve the efﬁ  cacy of telmisartan and to promote compliance 
in patient who otherwise would require the administration of 
two drugs. Combined therapy is available in three combina-
tions of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg 
telmisartan and hydrochlorothiazide, respectively.
Chemistry, pharmacology, 
pharmacodynamics, and pharmacokinetics 
of the compounds
Telmisartan is a long-acting, nonpeptide angiotensin II 
receptor-subtype 1 (AT1) antagonist, which is orally ac-Vascular Health and Risk Management 2007:3(3) 267
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tive, highly selective, and potent. It is chemically described 
as 4′-[(1,4′-dimethyl–2′-propyl[2,6′-bi-1H-benzimidazol]
1′-yl)methyl]-[1,1′-bipheny]-2-carboxylic acid. Telmisartan 
has the molecular formula C33H30N4O2; its molecular weight 
is 514.6 g/mol. It is a relatively lipophilic compound and has 
a higher n-octanol/buffer partition coefﬁ  cient (log p = 3.20) 
than candesartan (–0.96), irbesartan (1.48), valsartan (–0.95), 
or EXP-3174 (–2.45), the active metabolite of losartan 
(Wienen et al 2000). This high lipophilicity that is also re-
ﬂ  ected in its high volume of distribution (c. 500 L) (Stangier 
et al 2000) enhances tissue penetration, intracellular absorp-
tion, and bioavailability (Wienen et al 2000). 
Telmisartan lacks the tetrazole unit which is usually 
present in the structure of sartans, but has a common benz-
imidazole group with candesartan. The substitution of this 
benzimidazole moiety with a basic heterocycle results in 
potent AT1 antagonism and good absorption after oral ad-
ministration (Ries et al 1993). Telmisartan selectively and 
insurmountably inhibits stimulation of the AT1 receptor by 
angiotensin II without affecting other receptor systems in-
volved in cardiovascular regulation. It inhibits the binding of 
labeled angiotensin II to AT1 receptors in rat lung with a Ki of 
3.7 nmol/L (Wienen et al 1993). The drug dissociates slowly 
from AT1 receptors with a dissociation half-life of about 75 
minutes compared with 14.5 minutes for angiotensin II, and 
there appears to be no re-association of telmisartan with the 
receptor (Maillard et al 2002). This feature may explain why 
telmisartan has the longest half-life (approximately 24 hours) 
of all commercially available ARBs (Maillard et al 2001), 
making it suitable for once-daily dosing (Neutel et al 1998). 
Telmisartan blunts all the AT1-mediated effect of angiotensin 
II, including the vasoconstrictor and aldosterone-secreting 
effect of angiotensin II. It also inhibits the negative regula-
tory feedback of angiotensin II on renin secretion, but the 
resulting increases in plasma renin activity and angiotensin 
II circulating levels do not overcome the blockade exerted 
by telmisartan (Stangier et al 2001; de Gasparo 2004). In ad-
dition to its vasodilatory properties, telmisartan also appears 
to modulate renal function, an effect which may contribute 
to its antihypertensive efﬁ  cacy and has been demonstrated 
in vitro on isolated perfused kidneys (Wienen et al 1993) 
as well as in vivo in rats and dogs (Wienen and Entzeroth 
1994; Schierok et al 2001). Finally, In addition to its AT1 
receptor antagonism, telmisartan has also been identiﬁ  ed as 
an activator of the peroxisome proliferator-activated recep-
tor γ (PPAR-γ) (Benson et al 2004; Schupp et al 2004). The 
transcription factor PPAR-γ is a nuclear hormone receptor, 
which acts as a central regulator of insulin and glucose 
metabolism, improving insulin sensitivity. Full receptor 
agonists such as the thiazolidinidiones pioglitazone (Actos®; 
Eli Lilly) or rosiglitazone (Avendia®; GlaxoSmithKline) 
are approved for the indication of diabetes mellitus (Pittas 
and Greenberg 2002). Unfortunately, besides their insulin-
sensitizing effect these drugs also showed some adverse 
effects like weight gain, edema and ﬂ  uid retention (Zanchi 
et al 2004). In contrast, telmisartan showed only a partial 
agonistic activity for the PPAR-γ receptor and thus modulates 
the activity of PPAR-γ, retaining the metabolic efﬁ  cacy of 
PPAR-γ activation with reduction in adverse effects exerting 
in parallel with AT1 receptor blockade (Schupp et al 2005). 
This special feature (also present though in a smaller extend 
in other ARBs such as irbesartan (Schupp et al 2004) and 
losartan (Marshall et al 2006)) may provide a new thera-
peutic option for better cardiovascular risk management in 
metabolic diseases. Indeed, telmisartan that combines an-
tihypertensive and antidiabetic actions has been found in 
some preclinical and clinical studies to improve carbohydrate 
and lipid metabolisms without causing the side effects that 
accompany full PPAR-γ activators (Kurtz 2005). Yet, the 
clinical relevance of these effects of telmisartan on PPAR-γ 
receptors remains to be demonstrated on a large group of 
hypertensive patients.
Hydrochlorothiazide (HCTZ) is a sulfonamide derivative 
thiazide diuretic. Chemically it is described as 6-chloro-
3,4-dihydro-2H-1,2,4-benzothiadizine-7-sulfonamide 
1,1-dioxide. Its empirical formula is C7H8ClN3O4S2; and its 
molecular weight is 297.7 g/mol. Thiazide diuretics such 
as hydrochlorthiazide are widely used for the treatment of 
hypertension. Though the mechanism of the antihypertensive 
effect of thiazides is still not fully understood, it is obvious 
that these agents act by promoting sodium excretion leading 
to a transitory negative sodium balance. Thiazides affect 
the renal tubular mechanisms of electrolytes reabsorption 
in the distal segment of the nephron, directly increasing the 
excretion of sodium and chloride in approximately equivalent 
amounts by blocking the Na+Cl– co-transporter. Following 
oral administration of hydrochlorthiazide, urinary electro-
lytes and water excretion increase within 2 hours, peaks at 
4 hours, and the effect lasts for up to 24 hours.
Unfortunately, the drawback of such compounds is, as 
already mentioned, the secondary stimulation of the RAS 
resulting in an increase in aldosterone secretion which in turn 
causes a loss of potassium and a compensatory increase in 
proximal re-absorption of uric acid leading to hyperuricemia. 
These effects are responsible for two of the major side-effects 
of thiazide diuretics, ie, hypokalemia and gout (Reyes 2003). Vascular Health and Risk Management 2007:3(3) 268
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Of note, thiazide-induced hypokalemia can potentially trigger 
adverse cardiac events (Beermann and Groschinsky-Grind 
1977; Siscovick et al 1994).
The pharmacokinetics and pharmacodynamic proper-
ties of the telmisartan/hydrochlorothiazide combination 
have not been studied extensively in patients or healthy 
volunteers. For example, to date, only one study has been 
designed to compare the steady-state pharmacokinetics of 
a high-dose telmisartan with and without a high-dose of 
hydrochlorothiazide in order to compare the steady-state 
pharmacokinetics of hydrochlorothiazide and telmisartan 
given alone or in combination. This open-label, crossover 
study was done in 13 healthy volunteers. All subjects 
received telmisartan 160 mg qd, hydrochlorothiazide 25 
mg qd and telmisartan/hydrochlorothiazide 160/25 mg 
qd for 7 days. Each treatment phase was separated by a 
14-day washout period (Young et al 2000). The results 
showed that there were no appreciable differences in 
trough plasma concentrations of hydrochlorothiazide and 
telmisartan, given alone or in combination. Mean values 
of the primary end points (Cmax and AUC0-24) and sec-
ondary end points (Cmin and t1/2) for both telmisartan and 
hydrochlorothiazide were unaffected when administered 
simultaneously. Moreover, concurrent telmisartan had no 
effect on urinary excretion of hydrochlorothiazide. The 
absence of any significant effect on the pharmacokinetics 
of either hydrochlorothiazide or telmisartan demonstrates 
that no dose adjustment is required if the two agents are 
given together for the management of hypertension. 
In contrast to other ARBs, some drug interactions have 
been described with telmisartan. In particular, telmisartan 
increases (49% at peak and 30% at trough) serum digoxin 
concentration, and may also decrease plasma warfarin levels 
(Sharpe et al 2001). The administration of telmisartan did 
not result in clinically signiﬁ  cant interaction with acetamino-
phen, amlodipine, glibenclamide, simvastatin, ibuprofen, or 
hydrochlorothiazide. Since telmisartan had no effects in vitro 
on cytochrome P450 enzymes, except for some minimal in-
hibition of CYP2C19, it is not expected to interact with drugs 
that inhibit cytochrome P450 enzymes nor with drugs that are 
metabolized by cytochrome P450, except for possible inhibi-
tion for drugs metabolized by CYP2C19 (Unger and Kaschina 
2003). On the other hand, hydrochlorothiazide may potentially 
interact with a large variety of drugs. Thus, the absorption of 
hydrochlorothiazide is impaired in the presence of anionic 
exchange resins. Single doses of either cholestyramine or 
colestipol resins bind the hydrochlorothiazide and reduce its 
absorption from the gastrointestinal tract by up to 85% and 
43%, respectively. Thiazide diuretics reduce the renal clear-
ance of lithium and lead to a high risk of lithium toxicity. 
We have summarized in Table 1 the main pharmacody-
namics of telmisartan and hydrochlorothiazide separately. 
Indeed, apart from its antihypertensive action in rats (Wienen 
and Schierok 2001), no special report has been published on 
the pharmacodynamic properties of the telmisartan/hydro-
chlorothiazide combination itself. Therefore, the properties 
described in this table are from studies in animals, healthy 
volunteers, and patients receiving telmisartan or hydrochlo-
rothiazide as monotherapy. 
Clinical efﬁ  cacy of telmisartan/
hydrochlorothiazide
Numerous reviews dealing with the clinical antihyperten-
sive efﬁ  cacy of telmisartan/hydrochlorothiazide have been 
recently published (Fenton et al 2003; Schmieder 2004; 
Maillard and Burnier 2005; Meredith 2005; Battershill and 
Scott 2006). A series of large, multicenter, randomized, 
controlled clinical trials has been performed recently in order 
to evaluate the clinical efﬁ  cacy of this therapy (see Table 2). 
Different primary end points were deﬁ  ned in these studies: 
the reduction in DBP, either from baseline (Karlberg et al 
1999; Lacourcière et al 2001; McGill and Reilly 2001b; 
Lacourcière and Martin 2002; Freytag et al 2002) or to 
values inferior to 90 mmHg (Neutel et al 2002; Freytag et al 
2002); changes in ambulatory DBP and SBP (Lacourcière 
et al 2003); and decreases in supine SBP (Karlberg et al 
1999; Freytag et al 2001). In these controlled clinical trials 
with over 2500 patients, patients were exposed to telmis-
artan (20–160 mg) and concomitant hydrochlorothiazide 
(6.25–25 mg). These trials included one factorial design 
trial with combinations of telmisartan (20, 40, 80, 160 mg, 
or placebo) and hydrochlorothiazide (6.25, 13.5, 25 mg, or 
placebo) (McGill and Reilly 2001b). Four other studies of 
at least 6 months’ duration allowed the addition of hydro-
chlorothiazide for patients who either were not adequately 
controlled on the randomized monotherapy dose or had not 
achieved adequate response after a complete up-titration of 
telmisartan (Karlberg et al 1999; Freytag et al 2001, 2002; 
Neutel et al 2002). All these studies proved this combination 
both as ﬁ  xed-dose combination (Lacourcière et al 2001, 2003; 
McGill and Reilly 2001b; Lacourcière and Martin 2002) or 
as an add-on (Freytag et al 2001, 2002; Neutel et al 2002), 
to be highly effective in reducing BP (Maillard and Burnier 
2005), particularly in the early morning period (Lacourciere 
et al 2005). Combining telmisartan with hydrochlorothiazide 
enhances the antihypertensive activity of telmisartan in Vascular Health and Risk Management 2007:3(3) 269
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Table 1a Pharmacodynamic properties of telmisartan
In vivo (animals)
•  Dose-dependent inhibition of the pressor response to exogenous angiotensin II in rats (Chen et al 1993) and dogs (Wienen et al 2000)
•  Reduces blood pressure observed TGR (mREN)27 transgenic rats at oral doses of >0.5 mg/kg/day 
•  The compound was more potent than losartan in reducing mean arterial blood pressure in these transgenic rats (Van Meel et al 1996) 
•  Modulation of renal excretory function in isolated perfused rat kidneys (Wienen et al 1993)
•  Diuretic effects in rats and dogs (Wienen and Entzeroth 1994; Schierok et al 2001)
•  Decrease glomerulosclerosis and proteinuria as well as cardiac hypertrophy in different animal models of hypertension and diabetes (Böhm
  et al 1995, 1996; Wienen et al 2000, 2001)
•  After peripheral administration, penetrates the blood–brain barrier of rats in a dose- and time-dependent manner to inhibit centrally
  mediated effects of Ang II (Gohlke et al 2001) 
•  Partial agonist of PPARγ in rats fed a high-fat, high carbohydrate diet (Benson et al 2004)
•  Attenuates weight gain and decreases serum triglyceride and glucose levels vs losartan or vehicle in a rat model of diet-induced insulin
  resistance (Benson et al 2004)
•  Decreases cardiac hypertrophy in hypertensive or diabetic rat model (Sharpe et al 2001)
In vivo (humans)
•  Prolonged inhibition of angiotensin II-induced increase in blood pressure in normotensive volunteers (van Heiningen et al 1994; Stangier
  et al 2001)
•  The >25% inhibitory effect of telmisartan 80 mg to repeated angiotensin II challenge lasts >40 hours in healthy subjects (Stangier
  et al 2001)
•  Increases urinary Na+ excretion without increasing K+ and uric acid excretion in drug-free hypertensive patients (Fenton et al 2003)
•  Decreases cardiac hypertrophy in hypertensive patients (Mattioli et al 2004)
•  Reduces proteinuria in diabetic patients (Barnett et al 2004)
•  Decreases fasting insulin levels, serum triglyceride levels, high sensitivity C-reactive protein (Miura et al 2005)
• Signiﬁ  cant decrease in left ventricular hypertrophy after 3–24 months’ treatment in hypertensive patients (Mattioli et al 2004)
Table Ib Overview of the pharmacodynamic properties of hydrochlorothiazide 
•  Inhibits the Na+/Cl  – co-transporter in the distal convoluted tubule and thereby increase sodium excretion
•  Increases excretion of potassium K+ and may cause hypokalemia
•  Inhibits vascular smooth muscle cell carbonic anhydrase which results in an activation of potassium channels (Pickkers et al 1999)
•  May causes extracellular volume depletion, hyponatremia, hypochloremia, metabolic alkalosis, and hypercalcemia
•  Increases serum uric acid and may cause gout
•  Reduces blood pressure and reduces the incidence of cardiovascular events in hypertension (ALLHAT study)
•  May decrease glucose tolerance and unmask latent diabetes mellitus
•  May increase plasma concentrations of low density lipoprotein, total cholesterol, and total triglycerides
almost two-thirds of hypertensive patients with mild to mod-
erate hypertension. Moreover, because of their synergism, 
BP control can sometimes be achieved with lower doses of 
each component (Schmieder 2004; Maillard and Burnier 
2005). This is particularly interesting since the metabolic 
disturbances associated with high dose hydrochlorothiazide 
were avoided by combining low doses of this drug with 
telmisartan (Schmieder 2004).
When compared with other antihypertensive such as 
atenolol (Freytag et al 2001), amlodipine (Neldam and 
Edwards 2006), or enalapril (Karlberg et al 1999) given 
alone or in combination with hydrochlorothiazide, long-term 
studies demonstrated that telmisartan alone or combined 
with hydrochlorothiazide is at least as effective in treating 
high BP in patients with mild to moderate hypertension as 
these other drugs. 
Thus, for example, the antihypertensive efﬁ  cacy and 
tolerability of two doses of telmisartan and of the beta-
blocker atenolol were compared in patients with mild to 
moderate hypertension in a 26-week multicenter, random-
ized, double-blind, double-dummy, parallel-group trial 
(Freytag et al 2001). This study was conducted in 520 men 
and women aged 22–79 years with morning mean supine 
DBP between 95 and 114 mmHg and SBP <210 mmHg 
after a 2- to 3-week placebo run-in period. These patients 
were randomized in a 2:1 ratio to telmisartan (40 mg titrated 
to 80 mg or to 120 mg) or atenolol (50 mg titrated to 100 
mg) in order to obtain a DBP 90 mmHg or a decrease of 
DBP from baseline of 10 mmHg (primary efﬁ  cacy end 
point). Open-label hydrochlorothiazide 12.5 or 25 mg was 
added if needed according to a predeﬁ  ned titration rule. At 
the end of the study, 84% of the telmisartan and 78% of the Vascular Health and Risk Management 2007:3(3) 270
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atenolol-treated patients had achieved the primary end point 
(difference not statistically signiﬁ  cant), The ﬁ  nal reduction 
in SBP/DBP was 20.9/14.4 mmHg with telmisartan and 
16.7/13.3 mmHg with atenolol; only the difference in SBP 
between both regimen was signiﬁ  cant (p = 0.005). By week 
26, 32% of the telmisartan and 28% of the atenolol patients 
required hydrochlorothiazide. For these patients, additional 
mean reductions in supine SBP/SDP of 7.2/6.0 mmHg were 
observed when the diuretic was added to telmisartan therapy, 
and 6.6/3.5 mmHg when hydrochlorothiazide was added to 
atenolol therapy (Freytag et al 2001). 
Some studies have compared the efﬁ  cacy of the ARB-
diuretic therapy with other combinations in older patients. 
The ATHOS study has been designed to compare the changes 
in 24-hour ambulatory BP in 872 elderly with predominantly 
systolic hypertension receiving either telmisartan 80 mg/hy-
drochlorothiazide 12.5 mg or amlodipine 10 mg/hydrochlo-
rothiazide 12.5 mg in a prospective, randomized, open-label, 
blinded-end point trial. The results of this study (Neldam 
and Edwards 2006) showed that telmisartan/hydrochloro-
thiazide and amlodipine/hydrochlorothiazide changed SBP 
for the last 6 hours of the dosing interval by –18.3 and –17.4 
mmHg, respectively (p = 0.2520). However, telmisartan/hy-
drochlorothiazide provided signiﬁ  cantly greater reductions 
compared than amlodipine/hydrochlorothiazide over the 24-
hour period (–19.3 and –17.2 mmHg, respectively; p = 0.001) 
and provided higher SBP control rates (65.9% and 58.3%, 
respectively; p = 0.0175). Treatment effects were similar 
across age groups and in both men and women (Neldam 
and Edwards 2006).
On other hand, when compared with enalapril in elderly 
patients (65 years and over) in a 26-week, multicenter, 
double-blind, parallel-group, dose-titration study (Karlberg 
et al 1999), no signiﬁ  cant difference were observed in mean 
changes from baseline both in supine DBP (–12.8 mmHg for 
telmisartan and –11.4 mmHg for enalapril) or SBP (–22.1 
mmHg and –20.1 mmHg, respectively) at trough, and both 
regimens provided effective BP lowering over the 24-hour 
dosing interval, as determined by ambulatory BP monitoring. 
Both regimens were well tolerated; however, the incidence 
of treatment-related cough was signiﬁ  cantly higher with 
enalapril than with telmisartan (16 vs 6.5%). 
In another prospective, double-blind, randomized study 
(Barnett et al 2004) , enalapril and telmisartan were compared 
in patients with type 2 diabetes and early nephropathy. Two 
hundred and ﬁ  fty patients with normal levels of glomerular 
ﬁ  ltration rate (>90 mL/min per 1.73 m2 of body-surface area) 
were enrolled and receive either telmisartan 80 mg or enala-
pril 20 mg. Hydrochlorothiazide was given as concomitant 
therapy in more than 50% of patients in each group. After 5 
years of treatment, the adjusted mean reduction in SBP was 
6.9 mmHg with telmisartan and 2.9 mmHg with enalapril 
(95% CIl, –8.5 to 0.5 mmHg, not signiﬁ  cant). There was 
also no signiﬁ  cant difference between groups in DBP mean 
difference. Of note, the primary end point of this study was 
the change in glomerular ﬁ  ltration rate (GFR) from baseline 
to the last available value during the ﬁ  ve years of treatment. 
GFR decreased by17.9 mL/min per 1.73 m2 of body-surface 
area with telmisartan compared with 15.0 mL/min per 1.73 
m2 of body-surface area with enalapril, with a treatment dif-
ference of 2.6 mL/min. This difference was not signiﬁ  cant 
(Barnett et al 2004). 
Several other clinical studies have assessed the renal 
protective effect of telmisartan (Battershill and Scott 2006). 
Vogt et al (2005) recently published a substudy of the Angio-
tensin II Receptor Antagonist Micardis in Isolated Systolic 
hypertension (ARAMIS) Study in which they investigated 
the reduction in urinary albumin excretion in patients with 
isolated systolic hypertension (ISH) unselected for albumin-
uria. This study showed that telmisartan 20–80 mg induced 
a signiﬁ  cantly greater decrease in urinary albumin excre-
tion than hydrochlorothiazide 12.5 mg, irrespective of the 
baseline UAE, and despite comparable reductions in SBP 
with both drugs. 
Of note, based on the results of these studies and on 
the previous data from the RENAAL (Brenner et al 2001), 
IDNT (Lewis et al 2001), and IRMA II studies (Parving 
et al 2001), the telmisartan renoprotective study from in-
cipient nephropathy to overt nephropathy (INNOVATION) 
has been initiated (Makino et al 2005). This prospective, 
randomized, double-blind forced-titration, parallel-group, 
placebo-controlled study compares a high and low dose of 
telmisartan in 1800 hypertensive or normotensive Japanese 
patients. It will assess whether telmisartan provides clini-
cal beneﬁ  ts in hypertensive or normotensive patients with 
diabetes mellitus and diabetic nephropathy. This study has 
recently been completed and should be presented in 2006. 
In the same group of clinical studies (the PROTECTION 
trial program [Weber 2003]), two sister trials, VIVALDI in 
Europe and AMADEO in North America, will compare the 
potential beneﬁ  ts of telmisartan and valsartan (VIVALDI) 
(Boger et al 2005) or losartan (AMADEO) in the progression 
of renal disease in patients with diabetes and nephropathy. 
These two studies will be completed in early 2007.
Besides the antihypertensive effect of telmisartan and its 
potential ability to protect the kidney, telmisartan was also Vascular Health and Risk Management 2007:3(3) 272
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recently shown to be active in improving metabolic param-
eters, such as insulin resistance in hypertensive patients with 
coexisting type 2 diabetes or metabolic syndrome (Battershill 
and Scott 2006). However, none of these studies (Derosa 
et al 2004a, b; Miura et al 2005; Vitale et al 2005; Sengul 
et al 2006) involved patients under concomitant therapy with 
hydrochlorothiazide. 
Finally, the ability of telmisartan to reduce left ventricu-
lar hypertrophy (LVH) has been shown by several studies 
assessing left ventricular thickness or left ventricular mass 
as primary end point in mild to moderate hypertensive 
patients (Battershill and Scott 2006; Goebel et al 2006). A 
meta-analysis has identiﬁ  ed differences in the ability of dif-
ferent classes of anti-hypertensive agents to prevent or revert 
LVH, with agents that target the RAS appearing superior to 
other agents, such as beta-blockers and diuretics (Diez et al 
2001). In this context, in a recent 12-month, double-blind 
study in 69 patients with mild to moderate hypertension, left 
ventricular mass index (LVMI) was signiﬁ  cantly reduced 
from baseline with once-daily telmisartan 80 mg (141 vs 125 
g/m2; p < 0.001), whereas there was little change in patients 
receiving once-daily hydrochlorothiazide 25 mg (139 vs 
135 g/m2) (Galzerano et al 2004). The additional activity of 
telmisartan may probably be explained by the sustained BP 
control and the non-hemodynamic effects of targeting the 
RAS. The ultimate proof of the clinical value of telmisartan 
on reducing LVH will be provided by the outcome trials 
ONTARGET/TRANSCEND (Teo et al 2004) and PROTEC-
TION (Weber 2003) which will clarify the cardioprotective 
role of telmisartan in in high-risk patients whose BP is well 
controlled. 
Long-term exposure to telmisartan/
hydrochlorothiazide
Two open-label extension studies have been performed to 
assess the long-term efﬁ  cacy and tolerability of telmisartan 
40–80 mg administered once daily alone or in association 
with hydrochlorothiazide (12.5–25 mg). One study provided 
results over a 1-year treatment period (Neutel et al 2002) 
and in the second study, data were gathered for up to 4 years 
(Freytag et al 2002). 
In Neutel’s study, 483 patients had their treatment with 
telmisartan 80 mg/day titrated over 1 year with stepwise ad-
dition of hydrochlorothiazide 12.5 mg or 25 mg, and/or other 
antihypertensive drugs to achieve a DBP <90 mmHg (Neutel 
et al 2002). At the ﬁ  nal visit, DBP control was achieved in 
70.0% (194/277) of patients in the telmisartan monotherapy 
group and by 56%, 55%, and 65% of the patients receiving 
telmisartan/hydrochlorothiazide 80/12.5 mg/day, 80/25 mg/
day, or telmisartan 80 mg plus another antihypertensive with 
or without the hydrochlorothiazide (12.5 or 25 mg). Progres-
sively greater BP reductions occurred with the sequential 
addition of hydrochlorothiazide and other antihypertensives. 
All treatments were well tolerated (Neutel et al 2002).
The second long-term study assessing the efﬁ  cacy and 
tolerability of telmisartan combined with hydrochlorothiazide 
lasted 4 years (Freytag et al 2002). This open-label extension 
study of 4 controlled trials involved 888 patients with mild to 
moderate hypertension. Patients received telmisartan 40–80 
mg once daily with add-on hydrochlorothiazide (12.5–25 
mg) if necessary and/or other antihypertensives excluding 
other ARBs. The main goal was to lower supine DBP below 
90 mmHg. Almost 80% of the patients (701/888) completed 
the trial with a median exposure of 1184 days (>3 years). 
The proportion of responders was 89% in the telmisartan 
monotherapy (40 or 80 mg) treatment category after 8 weeks 
of treatment. However, this percentage dropped years to 
59% after 3 years, indicating that about one-third of patients 
initially responsive to telmisartan alone required additional 
therapy over time. With the addition of hydrochlorothiazide, 
in most cases 25 mg qd, the primary end point was reached 
in 75% of the patients who became unresponsive to the 
monotherapy. Most adverse events were of mild to moderate 
intensity and unrelated to treatment (Freytag et al 2002). 
Safety and tolerability
With an adverse-event proﬁ  le closely resembling that of 
placebo, telmisartan, like other ARBs, is characterized by a 
very high safety and tolerability, which has been conﬁ  rmed 
in several clinical trials (Fenton et al 2003; Battershill and 
Scott 2006) but also in a large, 6-month, post-marketing sur-
veillance study enrolling 19,870 patients (Michel et al 2004). 
The proﬁ  les of adverse events observed in these studies were 
similar in frequency and severity. Most adverse effects were 
mild and transient and occurred with a similar incidence in 
the placebo groups. Headache and dizziness were the most 
frequent adverse events. The tolerability and safety record 
of telmisartan is consistent across a wide range of patient 
demographic variables such as age, sex, and ethnic group 
(Battershill and Scott 2006). Neither the dry cough associated 
with ACE inhibitors nor the edema associated with calcium 
channel blockers (CCBs) has been observed with telmisartan 
treatment (White 2002).
The safety and tolerability of telmisartan/hydrochloro-
thiazide was investigated in most of the above-mentioned 
studies (Karlberg et al 1999; Lacourcière et al 2001; Freytag Vascular Health and Risk Management 2007:3(3) 273
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et al 2001; McGill and Reilly 2001a, b; Neutel et al 2002; 
Lacourcière and Martin 2002; Lacourcière et al 2003). 
The overall tolerability proﬁ  le was good, the incidence of 
adverse effects in the combination groups being similar to 
that observed in placebo-treated groups. For example, in 
the factorial design trial with combinations of telmisartan, 
hydrochlorothiazide, and placebo (McGill and Reilly 2001b), 
where all the 818 randomized patients were included in the 
safety analysis, adverse events were reported in 96 of 209 
(45.9%) patients receiving telmisartan monotherapy, 61 of 
121 (50.4%) receiving hydrochlorothiazide monotherapy, 
199 of 414 (48.1%) receiving combination therapy, and 31 of 
74 (41.9%) receiving placebo. Most adverse effects were mild 
in intensity and transient and did not require discontinuation 
of the therapy. No unexpected serious adverse events have 
been observed and adverse experiences have been limited 
to those that have been previously reported with telmisartan 
and/or hydrochlorothiazide. Thus, adverse events occurring 
in more than 2% of telmisartan/hydrochlorothiazide-treated 
patients were dizziness (5%), sinusitis and upper respira-
tory tract infection (4%–8%), fatigue (3%), inﬂ  uenza-like 
symptoms (2%), and gastrointestinal problems (nausea 2%, 
diarrhea 3%). In the same study, hydrochlorothiazide caused 
a dose-related decrease in serum potassium. Combination 
with telmisartan tended to offset the effects of hydrochlo-
rothiazide on serum potassium levels (McGill and Reilly 
2001b) (Figure 1).
Finally, a meta-analysis of data collected from 34 ran-
domized trials also concluded that the incidence of treatment-
related adverse events is similar in placebo-treated (10.5% 
n = 819) patients and patients receiving either telmisartan 
10–60 mg/day (12%, n = 6575) or telmisartan/hydrochloro-
thiazide 10–160/6.25–25 mg/day (12.8%, n = 2180) (Mancia 
2002). Of note, the incidence of treatment-related adverse 
events per patient per treatment year was higher in patients 
receiving placebo (1.02) than in patients on telmisartan 
monotherapy (0.20) or on combined telmisartan/hydrochlo-
rothiazide therapy (0.18) (statistical analysis not reported) 
(Mancia 2002). As with telmisartan alone, the most commonly 
reported adverse events in patients receiving telmisartan 
and hydrochlorothiazide were dizziness and headache and 
fatigue. In the same study, serious adverse events occurred 
less frequently in placebo recipients (1.1%) than in telmis-
artan-treated patients (5.6 % with hydrochlorothiazide and 
4.3% without hydrochlorothiazide, respectively). However, 
per patient per treatment year, the incidence was similar in all 
groups (Mancia 2002). Treatment-related hyperuricemia and 
hypokalemia occurred only in 5 and 6 patients, respectively, 
receiving combination therapy (Mancia 2002). 
Unfortunately, we have to emphasize that most of studies 
that have investigated the effect and the safety of the telmis-
artan/hydrochlorothiazide association have been short and 
medium term, and results of the longest ONTARGET and 
PROTECTION studies are not yet available. Generally, most 
of the longest prospective randomized trials in hypertension 
last only 4–6 years and therefore provide little if any infor-
mation on long-term safety, particularly for diuretics with 
or without combination with other antihypertensive drugs. 
Many patients are exposed to BP-lowering drugs for many 
decades, and drug-induced changes could be cumulative 
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(Grosmann and Messerli 2006). This is potentially true with 
the adverse metabolic effects that are seen with the diuretics. 
However, a combination with hydrochlorothiazide blunted 
the deleterious effect of diuretics decreasing the develop-
ment of new-onset diabetes in shorter-term experiments as 
observed in LIFE, SCOPE, and VALUE trials (Elliot 2005). 
Therefore we have to wait for cohort studies investigating 
morbidity and mortality of hypertensive patients which 
require an intervention on the RAS system to fully charac-
terize the long-term protective effect of combining an ARB 
with a thiazide diuretic. 
In all studies, adverse events occurred at approximately 
the same rate in men and women, older and younger patients 
(Karlberg et al 1999; Neldam and Edwards 2006), black and 
non-black patients (McGill and Reilly 2001a), and diabetic 
or non-diabetic (Fenton et al 2003). Long-term combination 
therapy is also well-tolerated as already mentioned in the 
4-year extension trial published by Freytag et al (Freytag 
et al 2002). 
Compared with other combined therapy, patients treated 
with telmisartan plus hydrochlorothiazide in the ATHOS 
study experienced fewer treatment-related adverse events 
than patients receiving amlodipine plus hydrochlorothiazide 
(8% vs 33%; p < 0.0001), with the incidence of peripheral 
edema being signiﬁ  cantly lower in the telmisartan combi-
nation therapy (1.2% vs 24.3%; p < 0.0001) (Neldam and 
Edwards 2006) (Figure 2). Relative to ACEIs, the incidence 
of treatment-related adverse events was similar for telmisar-
tan and enalapril (Karlberg et al 1999). However, as already 
mentioned above, more than twice as many patients taking 
enalapril experienced cough (16 vs 6.5%), which is believed 
to be caused by an accumulation of bradykinin that is not 
degraded in patients treated with an ACE inhibitor (Israili 
and Hall 1992) (Figure 3). 
Persistence on treatment
The more active drug will never be effective if it is not taken 
by the patient, and poor compliance is certainly an important 
cause of inadequate BP control. Several patient-related and 
physician-related parameters can affect drug adherence. 
There is, however, good evidence that drug-related issues 
can also interfere with the adherence to treatment. Thus the 
treatment complexity, the frequency of dosing, as well as the 
tolerability proﬁ  le of the drugs are important determinants 
of drug adherence.
One very common reason why patients do not comply 
with the prescription is the fact that they have to take several 
different medications with varying frequencies of dosing 
(Resnick 2003). This is an important contributory factor to 
poor compliance particularly in elderly patients (Wuerzner 
et al 2003). Therefore, efforts should been made to simplify 
drug regimens, and one appropriate intervention is to re-
duce the frequency of the drug administration as well as the 
number of agents to be taken. Indeed, a once-daily regimen 
induces a better compliance than a twice-daily regimen. This 
can be achieved using long-acting agents and ﬁ  xed-dose 
combinations which reduce the number of daily tablets. 
Several studies performed using ambulatory BP monitoring 
have shown that telmisartan shifts the entire BP proﬁ  le to 
lower levels including in the early morning period (Neutel 
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Figure 2 Drug-related adverse events, incidence of peripheral edema, and discontinuation rates in the ATHOS Study (derived from data of Neldam et al 2006).
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et al 1998; Lacourciere et al 2005). Moreover, the use of 
long-acting antihypertensive drugs such as telmisartan may 
prevent the rise in BP induced by a missed dose and may 
improve the 24-hour BP control even in the early morning 
hours before the next dose is taken (Willich et al 1987). 
In a recent meta-analysis presented at the European Meet-
ing of Hypertension, the efﬁ  cacy of ﬁ  xed-dose combinations 
to improve patient compliance therapy was compared with 
free-drug component regimens in patients with chronic 
disease (Bangalore et al 2006). Nine studies that reported 
medication compliance/adherence or persistence when using 
ﬁ  xed-dose combinations versus free-drug combinations were 
selected, of which 4 dealt with antihypertensive agents. In 
the hypertension studies, the authors showed that ﬁ  xed-dose 
combinations of antihypertensive drugs (amlodipine plus 
benazepril (Taylor and Shoheiber 2003), lisinopril plus 
hydrochlorothiazide or enalapril plus hydrochlorothiazide 
(Dezii 2000), and ARBs plus diuretic (Bangalore et al 2006)) 
improve compliance to medication by more than 50% when 
compared with free-drug combinations ((OR 1.54, 95% CI 
1.42–1.66). Such improvement in drug adherence should 
have an important impact on clinical outcomes. 
Another reason why hypertensive patients do not take 
their pills regurlarly is that they develop side-effects while 
the hypertension is usually asymptomatic (Brondolo et al 
1999). In this context, the excellent tolerability proﬁ  le of 
ARBs including telmisartan combined with hydrochloro-
thiazide is a potential advantage. Indeed, studies that have 
analyzed patterns of compliance and persistence (deﬁ  ned 
as continuing therapy with the originally prescribed antihy-
pertensive drug) have shown that both are intimately linked 
to tolerability (Kjellgren et al 1998; Conlin et al 2001; 
Wogen et al 2003). In a study of persistence that evaluated 
prescription reﬁ  ll data from 21,723 patients enrolled in a 
large pharmaceutical management organization (Bloom 
1998), the percentage of patients continuing initial ARB 
therapy was substantially higher at 12 months’ follow-up 
than the percentage continuing therapy with ACEIs, calcium 
antagonists, beta-blockers, or thiazide diuretics (64% vs 
58%, 50%, 43%, and 38%, respectively); and patients tak-
ing an ARB were more likely to continue with their initial 
therapy than those taking an ACEI, a calcium antagonist, a 
beta-blocker, or a thiazide diuretic (Bloom 1998). Another 
study determined whether the stay-on-therapy (persistence) 
patterns observed in a previous analysis at one year were 
maintained over a 4-year period. Signiﬁ  cantly more patients 
whose initial therapy was based on an ARB (losartan in 
this case) had continued with this treatment at 24 months 
(p < 0.007) and at 36 months (p < 0.01) compared with 
patients initially given drugs from other antihypertensive 
class. At 48 months, half (50.9%) of the original losartan-
prescribed group was still taking the initial agents whereas 
36.5% of the other antihypertensive cohorts remained on 
their initial drug class (Conlin et al 2001). In addition another 
study assessing persistence with antihypertensive therapy 
and discontinuation patterns in patients newly dispensed 
different antihypertensive drug classes in a natural Canadian 
population-based setting showed that compared with ARBs, 
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the likelihood of discontinuing therapy over the 39-month 
study period was signiﬁ  cantly higher for ACEIs (HR 1.29; 
95% CI 1.16−1.43), calcium antagonists (HR 1.42; 95% CI 
1.27−1.60), beta blockers (HR 1.62; 95% CI 1.45−1.80), and 
diuretics (HR 1.92; 95% CI 1.73−2.14). In the year following 
treatment discontinuation, between 54% and 75% of patients 
initiated a second course of treatment. Patients initiated on 
an ARB had a signiﬁ  cantly higher likelihood of starting a 
new course of therapy after a ﬁ  rst treatment discontinuation, 
compared with all other agents (Bourgault et al 2005). In 
the ATHOS study discussed before, the discontinuation rate 
was two-fold higher in the amlodipine-hydrochlorothiazide 
group than in the telmisartan/hydrochlorothiazide group (11.3 
compared with 5.0%; p < 0.001), mainly due to peripheral 
edema (Neldam and Edwards 2006).
Conclusion
Blockade of the RAS with selective AT1 receptor antagonists 
is recognized as an effective mean to lower BP in hyperten-
sive patients. Among AT1 receptor antagonists, telmisartan 
is characterized by a very long half-life. This enables smooth 
BP control over 24 hours using a once-daily administration 
and might result in potential clinical advantages such as 
greater compliance, sustained BP control, maintenance of 
control regardless of missing a dose, and reduced risk of 
cardiovascular events during the early morning hours. The 
preclinical data demonstrating the partial PPAR-γ agonis-
tic activity of telmisartan are of great interest considering 
the actual epidemiological trends of diabetes and obesity.   
However, whether these in vitro properties translate into 
real clinical beneﬁ  ts still needs clinical conﬁ  rmation in large 
groups of patients. 
The combination of telmisartan with hydrochlorothia-
zide is logical and also very effective. In accordance with 
past experiences using other compounds, several controlled 
studies have demonstrated that combining telmisartan with 
a low-dose thiazide is superior in lowering BP than either 
telmisartan or hydrochlorothiazide alone. Moreover, the 
excellent tolerability proﬁ  le of the ARB is not affected by 
the addition of a low-dose thiazide. 
Finally, ﬁ  xed-dose combinations are increasingly used 
in clinical practice in order to achieve the therapeutic goals 
deﬁ  ned by most national and international guidelines. The 
use of drugs combinations will probably increase further in 
future with the introduction of ﬁ  xed-dose combinations as 
possible ﬁ  rst-step therapies for hypertension according to Eu-
ropean guidelines (Cifkova et al 2003). American guidelines 
proposed the use of ﬁ  xed-dose combination as initial therapy 
in patients with stage 2 and 3 hypertension (Chobanian et al 
2003). Since the AT1 receptor antagonist/thiazide diuretic 
combination is an effective and well-tolerated drug associa-
tion, one might expect that the use of these combinations 
including that of telmisartan and hydrochlorothiazide will 
increase steadily over the next 5 years.
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